Pasithea Therapeutics Corp. reports news centered on PAS-004, its next-generation macrocyclic MEK inhibitor, and the company’s clinical-stage biotechnology operations. Recurring updates cover NF1-associated plexiform and cutaneous neurofibromas, advanced cancer, ALS-related research, FDA designations, clinical development strategy and medical leadership.
Company news also includes capital actions, investor conference presentations and public-company matters tied to common stock and warrant securities. Pasithea’s releases frame the business around drug-development progress, regulatory designations and financing activity supporting research, preclinical work and clinical trials.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.